
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 12)*

Kodiak Sciences Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

**Alexandra A. Toohey, CFO
860 Washington Street, 3rd Floor,
New York, NY, 10014
212-339-5690**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/28/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1 Name of reporting person

Baker Bros. Advisors LP

2 Check the appropriate box if a member of a Group (See Instructions)

	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
7	22,049,297.00
Number of	Shared Voting Power
Shares	
Beneficially	8 0.00
Owned by	Sole Dispositive Power
Each	9 22,049,297.00
Reporting	Shared Dispositive Power
Person	
With:	10 0.00
	Aggregate amount beneficially owned by each reporting person
11	22,049,297.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	35.0 %
	Type of Reporting Person (See Instructions)
14	IA, PN

SCHEDULE 13D

CUSIP No.

	Name of reporting person
1	Baker Bros. Advisors (GP) LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE
Number of	7 Sole Voting Power

Shares	
Beneficially	22,049,297.00
Owned by	Shared Voting Power
Each	8
Reporting	0.00
Person	Sole Dispositive Power
With:	9
	22,049,297.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	22,049,297.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	35.0 %
	Type of Reporting Person (See Instructions)
14	HC, OO

SCHEDULE 13D

CUSIP No.

	Name of reporting person
1	Julian C. Baker
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	UNITED STATES
	Sole Voting Power
7	22,049,297.00
Number of	Shared Voting Power
Shares	8
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	9
Reporting	22,049,297.00
Person	Shared Dispositive Power
With:	10
	0.00
11	Aggregate amount beneficially owned by each reporting person

	22,049,297.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	35.0 %
14	Type of Reporting Person (See Instructions)
	IN, HC

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	Felix J. Baker
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
4	Source of funds (See Instructions)
	OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	UNITED STATES
	Sole Voting Power
7	22,049,297.00
	Shared Voting Power
8	0.00
	Sole Dispositive Power
9	22,049,297.00
	Shared Dispositive Power
10	0.00
	Aggregate amount beneficially owned by each reporting person
11	22,049,297.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	35.0 %
14	Type of Reporting Person (See Instructions)
	IN, HC

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

- (a) Common Stock, \$0.0001 par value per share
- Name of Issuer:
- (b) Kodiak Sciences Inc.
- Address of Issuer's Principal Executive Offices:
- (c) 1250 Page Mill Road, Palo Alto, CALIFORNIA , 94304.

Item 1 Comment: This Amendment No. 12 to Schedule 13D amends and supplements the previously filed Schedule 13D filed by Baker Bros. Advisors LP (the "Adviser"), Baker Bros. Advisors (GP) LLC (the "Adviser GP"), Julian C. Baker and Felix J. Baker (collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. The Adviser GP is the sole general partner of the Adviser. Pursuant to management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds"), and their respective general partners, the Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosure in Item 5 below is incorporated herein by reference.

Item 4. Purpose of Transaction

Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosures in Item 5 below are incorporated herein by reference. This Amendment No. 12 is being filed to report the acquisition of common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in Item 5(c) that resulted in a more than 1 percent change in beneficial ownership. The disclosure regarding the purchases in Item 5(c) below is incorporated herein by reference. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer's management, other members of the Board and other investors, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, exercise of some or all of the Stock Options (as defined below) to purchase Common Stock of the Issuer) or to dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control. Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

The disclosures in the Reporting Persons' cover pages and in Item 4 are incorporated by reference herein. Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 12 are incorporated herein by reference. The percentage of beneficial ownership for each of the Reporting Persons reported herein is based on 62,849,457 shares of Common Stock outstanding as of August 6, 2026 as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission ("SEC") on August 13, 2026 plus 188,356 vested non-qualified options exercisable for 188,356 shares of Common Stock ("Stock Options") received by Felix J. Baker as compensation for his service on the Board. Set forth in Exhibit 99.1 is the aggregate number of shares of Common Stock directly held by each of the Funds, which may be deemed to be indirectly beneficially owned by the Reporting Persons along with the percentage of Common Stock held by each of the Funds.

- (a)
- (b) Items 7 through 10 of each of the cover pages of this Amendment No. 12 are incorporated herein by reference. The disclosure in Item 5(a) is incorporated herein by reference. The direct holdings of the Funds are detailed in Exhibit 99.1, which is incorporated herein by reference. Felix J. Baker, a managing member of the Adviser GP, currently serves on the Board. He is Chair of the Compensation Committee and serves on the Nominating/Governance Committee. Felix J. Baker, as compensation for his service on the Board, receives Stock Options. Felix J. Baker holds

24,747 vested Stock Options that have an exercise price of \$10.13 per share expiring June 2, 2029, 4,135 vested Stock Options that have an exercise price of \$62.50 per share expiring June 7, 2030, 7,106 vested Stock Options that have an exercise price of \$54.12 per share expiring June 29, 2030, 7,368 vested Stock Options that have an exercise price of \$93.00 per share expiring June 29, 2031, 25,000 vested Stock Options that have an exercise price of \$7.64 per share expiring June 29, 2032, 40,000 vested Stock Options that have an exercise price of \$6.90 per share expiring June 29, 2033, 40,000 vested Stock Options that have an exercise price of \$2.35 per share expiring June 27, 2034, 40,000 vested Stock Options that have an exercise price of \$3.73 per share expiring June 29, 2035, and 17,731 options to purchase 17,731 shares of Common Stock which were granted on June 30, 2026, that have an exercise price of \$38.96 per share expiring June 29, 2036, which will vest on the earlier of June 30, 2027 or one day prior to the next annual meeting of the Issuer's stockholders. The policies of the Funds and the Adviser do not permit managing members of the Adviser GP to receive compensation for serving as a director of the Issuer, and the Funds are instead entitled to the pecuniary interest in any compensation received for Felix J. Baker's service on the Board. The Adviser, the Adviser GP, and Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of the Stock Options held by Felix J. Baker disclosed herein and in previous amendments to this Schedule 13D. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

(c) The transactions in Common Stock detailed in Exhibit 99.2 were effected by the Adviser on behalf of the Funds during the sixty days preceding the filing of this statement. All transactions were effected in the over-the-counter market directly with a broker-dealer. Except as disclosed herein, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past sixty days.

(d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the managing members of Baker Biotech Capital (GP), LLC. Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the managing members of Baker Brothers Life Sciences Capital (GP), LLC.

(e) Not applicable.

Item 7. Material to be Filed as Exhibits.

99.1 Holding by the Funds in Securities of the Issuer 99.2 Item 5(c) Transactions in Common Stock

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Baker Bros. Advisors LP

Signature: /s/ Scott L. Lessing

Name/Title: Scott L. Lessing/ President By: Baker Bros.
Advisors (GP) LLC, its general partner

Date: 09/30/2026

Baker Bros. Advisors (GP) LLC

Signature: /s/ Scott L. Lessing

Name/Title: Scott L. Lessing/ President

Date: 09/30/2026

Julian C. Baker

Signature: /s/ Julian C. Baker

Name/Title: Julian C. Baker

Date: 09/30/2026

Felix J. Baker

Signature: /s/ Felix J. Baker

Name/Title: Felix J. Baker

Date: 09/30/2026

Holder	Common Stock	Percent of Class Outstanding
667, L.P.	1,669,727	2.7%
Baker Brothers Life Sciences, L.P.	20,191,214	32.1%
Total	21,860,941	34.8%

Name	Date	Number of Shares	Transaction	Price/Share	Footnote
667, L.P.	9/28/2026	856	Purchase	61.2104	1
Baker Brothers Life Sciences, L.P.	9/28/2026	14,344	Purchase	61.2104	1
667, L.P.	9/28/2026	2,666	Purchase	61.6252	2
Baker Brothers Life Sciences, L.P.	9/28/2026	44,690	Purchase	61.6252	2
667, L.P.	9/28/2026	243	Purchase	62.9623	3
Baker Brothers Life Sciences, L.P.	9/28/2026	4,067	Purchase	62.9623	3
667, L.P.	9/28/2026	479	Purchase	64.4276	4
Baker Brothers Life Sciences, L.P.	9/28/2026	8,021	Purchase	64.4276	4
667, L.P.	9/28/2026	321	Purchase	67.0967	5
Baker Brothers Life Sciences, L.P.	9/28/2026	5,382	Purchase	67.0967	5
667, L.P.	9/28/2026	154	Purchase	68.3736	6
Baker Brothers Life Sciences, L.P.	9/28/2026	2,585	Purchase	68.3736	6
667, L.P.	9/28/2026	2,331	Purchase	68.9578	7
Baker Brothers Life Sciences, L.P.	9/28/2026	39,066	Purchase	68.9578	7
667, L.P.	9/28/2026	1,056	Purchase	71.4843	8
Baker Brothers Life Sciences, L.P.	9/28/2026	17,698	Purchase	71.4843	8
667, L.P.	9/28/2026	16,641	Purchase	72.3873	9
Baker Brothers Life Sciences, L.P.	9/28/2026	278,978	Purchase	72.3873	9
667, L.P.	9/28/2026	4,696	Purchase	73.0777	10
Baker Brothers Life Sciences, L.P.	9/28/2026	78,726	Purchase	73.0777	10
667, L.P.	9/28/2026	4,577	Purchase	73.9686	11
Baker Brothers Life Sciences, L.P.	9/28/2026	76,723	Purchase	73.9686	11
667, L.P.	9/28/2026	1,924	Purchase	75.5151	12
Baker Brothers Life Sciences, L.P.	9/28/2026	32,261	Purchase	75.5151	12
667, L.P.	9/28/2026	3,681	Purchase	76.3450	13
Baker Brothers Life Sciences, L.P.	9/28/2026	61,700	Purchase	76.3450	13
667, L.P.	9/28/2026	2,884	Purchase	77.4314	14
Baker Brothers Life Sciences, L.P.	9/28/2026	48,350	Purchase	77.4314	14
667, L.P.	9/28/2026	2,969	Purchase	78.5681	15
Baker Brothers Life Sciences, L.P.	9/28/2026	49,771	Purchase	78.5681	15
667, L.P.	9/28/2026	534	Purchase	79.4045	16
Baker Brothers Life Sciences, L.P.	9/28/2026	8,956	Purchase	79.4045	16
667, L.P.	9/28/2026	17	Purchase	79.6300	
Baker Brothers Life Sciences, L.P.	9/28/2026	283	Purchase	79.6300	
667, L.P.	9/28/2026	884	Purchase	79.7076	17
Baker Brothers Life Sciences, L.P.	9/28/2026	14,827	Purchase	79.7076	17
667, L.P.	9/28/2026	404	Purchase	80.2259	18
Baker Brothers Life Sciences, L.P.	9/28/2026	6,783	Purchase	80.2259	18
667, L.P.	9/28/2026	61	Purchase	80.5200	
Baker Brothers Life Sciences, L.P.	9/28/2026	1,027	Purchase	80.5200	
667, L.P.	9/28/2026	1,024	Purchase	81.0204	19
Baker Brothers Life Sciences, L.P.	9/28/2026	17,159	Purchase	81.0204	19
667, L.P.	9/28/2026	338	Purchase	81.2019	20
Baker Brothers Life Sciences, L.P.	9/28/2026	5,654	Purchase	81.2019	20

Name	Date	Number of Shares	Transaction	Price/Share	Footnote
667, L.P.	9/28/2026	1,044	Purchase	81.3139	21
Baker Brothers Life Sciences, L.P.	9/28/2026	17,490	Purchase	81.3139	21
667, L.P.	9/28/2026	1,672	Purchase	81.8162	22
Baker Brothers Life Sciences, L.P.	9/28/2026	28,028	Purchase	81.8162	22
667, L.P.	9/28/2026	39	Purchase	81.9150	
Baker Brothers Life Sciences, L.P.	9/28/2026	651	Purchase	81.9150	
667, L.P.	9/28/2026	101	Purchase	82.6822	23
Baker Brothers Life Sciences, L.P.	9/28/2026	1,699	Purchase	82.6822	23
667, L.P.	9/28/2026	1,167	Purchase	83.1552	24
Baker Brothers Life Sciences, L.P.	9/28/2026	19,554	Purchase	83.1552	24
667, L.P.	9/28/2026	7,390	Purchase	83.9512	25
Baker Brothers Life Sciences, L.P.	9/28/2026	123,888	Purchase	83.9512	25
667, L.P.	9/28/2026	6,553	Purchase	84.8543	26
Baker Brothers Life Sciences, L.P.	9/28/2026	109,842	Purchase	84.8543	26
667, L.P.	9/28/2026	2,322	Purchase	85.9656	27
Baker Brothers Life Sciences, L.P.	9/28/2026	38,932	Purchase	85.9656	27
667, L.P.	9/28/2026	186	Purchase	86.7217	28
Baker Brothers Life Sciences, L.P.	9/28/2026	3,114	Purchase	86.7217	28
667, L.P.	9/28/2026	957	Purchase	86.8142	29
Baker Brothers Life Sciences, L.P.	9/28/2026	16,036	Purchase	86.8142	29
667, L.P.	9/28/2026	3,790	Purchase	86.9421	30
Baker Brothers Life Sciences, L.P.	9/28/2026	63,539	Purchase	86.9421	30
667, L.P.	9/28/2026	4,485	Purchase	87.5065	31
Baker Brothers Life Sciences, L.P.	9/28/2026	75,176	Purchase	87.5065	31
667, L.P.	9/28/2026	5,880	Purchase	88.5671	32
Baker Brothers Life Sciences, L.P.	9/28/2026	98,561	Purchase	88.5671	32
667, L.P.	9/28/2026	6,428	Purchase	88.6460	33
Baker Brothers Life Sciences, L.P.	9/28/2026	107,772	Purchase	88.6460	33
667, L.P.	9/28/2026	4,932	Purchase	89.6036	34
Baker Brothers Life Sciences, L.P.	9/28/2026	82,673	Purchase	89.6036	34
667, L.P.	9/28/2026	11,729	Purchase	89.8555	35
Baker Brothers Life Sciences, L.P.	9/28/2026	196,608	Purchase	89.8555	35
667, L.P.	9/29/2026	619	Purchase	84.2421	36
Baker Brothers Life Sciences, L.P.	9/29/2026	10,381	Purchase	84.2421	36
667, L.P.	9/29/2026	1,195	Purchase	85.4030	37
Baker Brothers Life Sciences, L.P.	9/29/2026	20,031	Purchase	85.4030	37
667, L.P.	9/29/2026	84	Purchase	85.8855	38
Baker Brothers Life Sciences, L.P.	9/29/2026	1,416	Purchase	85.8855	38

(1) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$60.50 to \$61.42. The Reporting Persons undertake to provide the staff of the Securities and Exchange Commission (the “Staff”), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(2) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$61.44 to \$62.43. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(3) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$62.48 to \$63.46. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(4) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$63.72 to \$64.66. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(5) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$66.86 to \$67.23. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(6) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$68.28 to \$68.50. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(7) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$68.65 to \$69.52. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(8) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$70.80 to \$71.76. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(9) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$71.77 to \$72.765. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(10) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$72.77 to \$73.77. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(11) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$73.88 to \$74.86. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(12) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$74.88 to \$75.86. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(13) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$75.88 to \$76.88. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(14) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$76.94 to \$77.88. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(15) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$77.92 to \$78.91. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(16) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$79.07 to \$79.55. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(17) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$79.44 to \$80.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(18) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$80.00 to \$80.79. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(19) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$80.455 to \$81.21. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(20) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$80.935 to \$81.73. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(21) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$81.31 to \$81.46. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(22) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$81.27 to \$82.22. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(23) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$82.52 to \$82.95. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(24) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$82.66 to \$83.38. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(25) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$83.39 to \$84.39. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(26) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$84.41 to \$85.40. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(27) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$85.50 to \$86.47. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(28) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$86.70 to \$86.75. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(29) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$86.47 to \$87.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(30) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$86.47 to \$87.465. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(31) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$87.03 to \$88.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(32) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$88.25 to \$88.97. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(33) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$88.01 to \$89.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(34) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$89.32 to \$90.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(35) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$89.11 to \$90.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(36) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$83.81 to \$84.65. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(37) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$85.16 to \$85.99. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

(38) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$85.82 to \$85.95. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
